- history of or need for hospitalization for the medical treatment of covid-19 - prior to current disease episode, any confirmed sars-cov-2 infection - known medical history of active liver disease - receiving dialysis or have known moderate to severe renal impairment - known human immunodeficiency virus (hiv) infection with a viral load greater than 400 copies/ml or taking prohibited medications for hiv treatment - suspected or confirmed concurrent active systemic infection other than covid-19 - history of hypersensitivity or other contraindication to any of the components of the study intervention - current or expected use of any medications or substances that are highly dependent on cyp3a4 for clearance or are strong inducers of cyp3a4 - has received or is expected to receive convalescent covid-19 plasma - has received or is expected to receive any dose of a sars-cov-2 vaccine before the day 34 visit - participating in another interventional clinical study with an investigational compound or device, including those for covid-19 through the long-term follow-up visit - known prior participation in this trial or other trial involving pf-07321332 - oxygen saturation of <92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition - females who are pregnant or breastfeeding

- history of or need for hospitalization for the medical treatment of covid-19 - prior to current disease episode, any confirmed sars-cov-2 infection - known medical history of active liver disease - receiving dialysis or have known moderate to severe renal impairment - known human immunodeficiency virus (hiv) infection with a viral load greater than 400 copies/ml or taking prohibited medications for hiv treatment - suspected or confirmed concurrent active systemic infection other than covid-19 - history of hypersensitivity or other contraindication to any of the components of the study intervention - current or expected use of any medications or substances that are highly dependent on cyp3a4 for clearance or are strong inducers of cyp3a4 - has received or is expected to receive convalescent covid-19 plasma - has received or is expected to receive any dose of a sars-cov-2 vaccine before the day 34 visit - participating in another interventional clinical study with an investigational compound or device, including those for covid-19 through the long-term follow-up visit - known prior participation in this trial or other trial involving pf-07321332 - oxygen saturation of <92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition - females who are pregnant or breastfeeding